19,100 Shares in DaVita Inc. (NYSE:DVA) Purchased by Quantedge Capital Pte Ltd

Quantedge Capital Pte Ltd purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 19,100 shares of the company's stock, valued at approximately $2,856,000.

Several other hedge funds have also added to or reduced their stakes in the business. Quantinno Capital Management LP boosted its holdings in DaVita by 61.8% in the 4th quarter. Quantinno Capital Management LP now owns 28,147 shares of the company's stock valued at $4,209,000 after purchasing an additional 10,753 shares during the period. Mufg Securities Americas Inc. bought a new stake in shares of DaVita during the 4th quarter worth $100,000. Occudo Quantitative Strategies LP acquired a new stake in shares of DaVita in the 4th quarter valued at approximately $290,000. NDVR Inc. grew its stake in shares of DaVita by 28.9% during the fourth quarter. NDVR Inc. now owns 1,714 shares of the company's stock worth $256,000 after buying an additional 384 shares during the last quarter. Finally, Lighthouse Investment Partners LLC acquired a new position in DaVita in the 4th quarter worth about $1,645,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DaVita stock traded up $1.73 during trading hours on Tuesday, hitting $146.69. 275,187 shares of the company's stock traded hands, compared to its average volume of 828,716. The stock has a market capitalization of $11.08 billion, a price-to-earnings ratio of 13.66, a PEG ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 12-month low of $131.44 and a 12-month high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company has a fifty day simple moving average of $145.72 and a 200-day simple moving average of $153.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the previous year, the firm posted $2.26 earnings per share. The company's revenue for the quarter was up 5.0% on a year-over-year basis. Equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Truist Financial reduced their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday. StockNews.com raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.